Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET

Company Participants

Danielle Dudgeon - Stern Investor Relations

Kevin Boyle - Chief Executive Officer

Drew Deniger - Vice President of Research and Development

Abhishek Srivastava - Vice President of Technical Operations

Mike Wong - Vice President of Finance

Conference Call Participants

Prakhar Agrawal - Cantor Fitzgerald

Thomas Flaten - Lake Street Capital Markets

Yale Jen - Laidlaw & Company

Swayampakula Ramakanth - H.C. Wainwright

Operator

Good day and thank you for standing by. Welcome to the Alaunos Therapeutics' Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference maybe recorded.

I will like to hand the conference over to your speaker today, Danielle Dudgeon, with Stern Investor Relations. Please go ahead.

Danielle Dudgeon

Good morning, and welcome to Alaunos Therapeutics second quarter 2022 financial results conference call and audio webcast. With me today are Kevin Boyle Senior, Chief Executive Officer; Drew Deniger, Vice President of Research and Development; Abhishek Srivastava, Vice President of Technical Operations; and Mike Wong, Vice President of Finance.

Earlier this morning, Alaunos issued a press release announcing financial results for the three months ended June 30, 2022. We encourage everyone to read today's press release, as well as the Alaunos quarterly report on Form 10-Q for the quarter ended June 30, 2022, which is filed this morning with the SEC. The company's press release and quarterly report will also be available one the Alaunos' Web site at Alaunos.com. In addition, this conference call is being webcast through the Investor Relations section of the company's Web site, and will be archived there for future reference.

Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 15, 2022. Actual results could differ materially from those stated or implied by the forward-looking statements made today due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at ec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law.